AgomAb Therapeutics (AGMB) Stock
What AgomAb Therapeutics's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -3.73x
What AgomAb Therapeutics's price implies
AgomAb Therapeutics's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Net income | -11M EUR | -46M EUR | -63M EUR |
| Free cash flow | — | -48M EUR | -52M EUR |
| EPS (diluted) | -35.63 EUR | -107.09 EUR | -143.22 EUR |
| Operating margin | — | — | — |
Superinvestors who own AGMB
From each investor's latest 13F filing (what a 13F shows). All 2 holders
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Wilmot Harkey Nantahala Capital Management | Added | $20M | 1.2% | Q2 2026 |
| Two Sigma Two Sigma Investments | Added | $234,575 | 0.0% | Q2 2026 |
AgomAb Therapeutics insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you). Every purchase
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Nov 5, 2026 | R Epstein David Director | 5,000 | $6.81 | $34,050 |
| Oct 21, 2026 | R Epstein David Director | 5,000 | $8.86 | $44,300 |
| Oct 8, 2026 | R Epstein David Director | 5,000 | $8.90 | $44,500 |
| Oct 6, 2026 | Thadee Victor Kemula Pierre Chief Financial Officer | 5,000 | $8.57 | $42,850 |
| Oct 6, 2026 | Thadee Victor Kemula Pierre Chief Financial Officer | 2,000 | $8.54 | $17,080 |
| Oct 6, 2026 | R Epstein David Director | 5,000 | $8.70 | $43,500 |
| Oct 6, 2026 | Jasper Knotnerus Tim Chief Executive Officer | 5,000 | $8.70 | $43,500 |
| Oct 6, 2026 | Thadee Victor Kemula Pierre Chief Financial Officer | 3,000 | $8.67 | $26,010 |
| Oct 5, 2026 | Jasper Knotnerus Tim Chief Executive Officer | 6,000 | $8.48 | $50,880 |
| Oct 5, 2026 | R Epstein David Director | 5,000 | $8.57 | $42,850 |
Fundamental grade
Five factors scored 1 to 9 from AGMB's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How AgomAb Therapeutics compares
AgomAb Therapeutics's ROE is higher than 27% of Healthcare companies and 9% of the 3,460 companies with an ROE figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| ROE | 27% | 9% |
Questions about AgomAb Therapeutics
Are AgomAb Therapeutics insiders buying the stock?
10 open-market insider purchases of AGMB in the last 12 months, from SEC Form 4 filings.
Which superinvestors own AgomAb Therapeutics?
2 of the superinvestors Investingly tracks hold AGMB in their latest 13F, including Wilmot Harkey, Two Sigma.
Companies like AgomAb Therapeutics
Crescent Biopharma, Inc. (CBIO)$376MRezolute, Inc. (RZLT)$375MContineum Therapeutics, Inc. Class A Common Stock (CTNM)$374MAvalo Therapeutics Inc (AVTX)$374MLyell Immunopharma, Inc. (LYEL)$365MSurrozen, Inc./DE (SRZN)$364MAllogene Therapeutics Inc (ALLO)$360MZura Bio Ltd (ZURA)$394MEupraxia Pharmaceuticals Inc. Common Stock (EPRX)$358M All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.